Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 212614
Company: BOEHRINGER INGELHEIM
Company: BOEHRINGER INGELHEIM
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
TRIJARDY XR | EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE | 5MG;2.5MG;1GM | TABLET, EXTENDED RELEASE;ORAL | Prescription | None | Yes | No |
TRIJARDY XR | EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE | 10MG;5MG;1GM | TABLET, EXTENDED RELEASE;ORAL | Prescription | None | Yes | No |
TRIJARDY XR | EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE | 12.5MG;2.5MG;1GM | TABLET, EXTENDED RELEASE;ORAL | Prescription | None | Yes | No |
TRIJARDY XR | EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE | 25MG;5MG;1GM | TABLET, EXTENDED RELEASE;ORAL | Prescription | None | Yes | Yes |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
01/27/2020 | ORIG-1 | Approval | Type 4 - New Combination | STANDARD |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212614s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/212614Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212614Orig1s000TOC.cfm |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
10/30/2023 | SUPPL-20 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212614s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/206073Orig1s036; 206111Orig1s042; 208658Orig1s028; 212614Orig1s020ltr.pdf | |
10/13/2022 | SUPPL-16 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212614s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/212614Orig1s016ltr.pdf | |
06/11/2021 | SUPPL-10 | Labeling |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212614s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/204629Orig1s028, s029; 206073Orig1s027, s030; 206111Orig1s025, s026; 208658Orig1s013, s015; 212614Orig1s008, s010ltr.pdf | |
06/11/2021 | SUPPL-8 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212614s008s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/204629Orig1s028, 206073Orig1s027, 206111Orig1s025, 208658Orig1s013, 212614Orig1s008ltr.pdf | |
10/30/2020 | SUPPL-4 | Efficacy-Labeling Change With Clinical Data |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212614s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/212614Orig1s004ltr.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
10/30/2023 | SUPPL-20 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212614s020lbl.pdf | |
10/13/2022 | SUPPL-16 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212614s016lbl.pdf | |
06/11/2021 | SUPPL-10 | Labeling | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212614s008s010lbl.pdf | |
06/11/2021 | SUPPL-8 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212614s008s010lbl.pdf | |
10/30/2020 | SUPPL-4 | Efficacy-Labeling Change With Clinical Data | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212614s004lbl.pdf | |
01/27/2020 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212614s000lbl.pdf |